| Dr Sara V Sanz Lebron, MD | |
|
T9 Villas De Playa 2, Dorado Del Mar, Dorado, PR 00646 | |
| (904) 860-4857 | |
| Not Available |
| Full Name | Dr Sara V Sanz Lebron |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 33 Years |
| Location | T9 Villas De Playa 2, Dorado, Puerto Rico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750360590 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Puerto Rico Pathology Associates P | 4385655760 | 14 |
News Archive
A new study from Columbia University School of Nursing supports a growing body of evidence that women are less likely to contract bloodstream or surgical site infections than their male counterparts.
There is increasing evidence to include combined neoadjuvant chemoradiotherapy (CRT) as an alternative to surgical resection alone, to improve survival for locoregional esophageal cancer. More recently, attention has focused on the presence of extracapsular lymph node involvement (LNI), which identifies a subgroup of patients with significantly worse long-term survival. Little is known about the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular LNI and its prognostic value in patients with resected esophageal cancer.
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation.
BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 3 days ago
| Entity Name | Puerto Rico Pathology Associates P |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740246545 PECOS PAC ID: 4385655760 Enrollment ID: O20060523000117 |
News Archive
A new study from Columbia University School of Nursing supports a growing body of evidence that women are less likely to contract bloodstream or surgical site infections than their male counterparts.
There is increasing evidence to include combined neoadjuvant chemoradiotherapy (CRT) as an alternative to surgical resection alone, to improve survival for locoregional esophageal cancer. More recently, attention has focused on the presence of extracapsular lymph node involvement (LNI), which identifies a subgroup of patients with significantly worse long-term survival. Little is known about the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular LNI and its prognostic value in patients with resected esophageal cancer.
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation.
BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sara V Sanz Lebron, MD T9 Villas De Playa 2, Dorado Del Mar, Dorado, PR 00646 Ph: (904) 860-4857 | Dr Sara V Sanz Lebron, MD T9 Villas De Playa 2, Dorado Del Mar, Dorado, PR 00646 Ph: (904) 860-4857 |
News Archive
A new study from Columbia University School of Nursing supports a growing body of evidence that women are less likely to contract bloodstream or surgical site infections than their male counterparts.
There is increasing evidence to include combined neoadjuvant chemoradiotherapy (CRT) as an alternative to surgical resection alone, to improve survival for locoregional esophageal cancer. More recently, attention has focused on the presence of extracapsular lymph node involvement (LNI), which identifies a subgroup of patients with significantly worse long-term survival. Little is known about the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular LNI and its prognostic value in patients with resected esophageal cancer.
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation.
BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 3 days ago